

*You are invited to attend a
presentation on*

Evaluating Attruby for Patients With ATTR-CM: An Overview

Date

Wednesday, March 18, 2026

Time

06:30 PM EST

Or & iron

8485 Dani Drive,
Fort Myers, FL 33966
(239) 396-4351

Presented by

David G Wolinsky, MD, FACC, MASNC
Section Head Emeritus of Nuclear Cardiology,
Medical Director Emeritus of Cardiac
Amyloidosis Center
Cleveland Clinic Florida

Hosted by

Lisa Johnson
lisa.johnson@bridgebio.com
(412) 477-4717

Registration

[https://rsvp.bridgebio.cm-go.com/
home/index/BR-32331](https://rsvp.bridgebio.cm-go.com/home/index/BR-32331)

SCAN THE QR CODE
NOW TO REGISTER



INDICATION

Attruby[®] (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

SELECT SAFETY INFORMATION

Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Increase in serum creatinine and decrease in eGFR may occur within 4 weeks of starting Attruby and then stabilize. The laboratory changes were reversible after treatment discontinuation.

*Please see additional Important Safety Information on the reverse side and accompanying full **Prescribing Information**.*

NOTE: This program is intended for healthcare professionals only. You may receive certain transfers of value and/or in-kind benefits from BridgeBio Inc. in connection with your attendance at this program. BridgeBio Inc. will report such transfers of value and/or in-kind benefits in accordance with Federal and/or State requirements. Minnesota, New Jersey, Vermont, and Federal Entities (e.g., VA, DoD) have restrictions on receiving certain transfers of value and/or in-kind benefits at industry-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, BridgeBio Inc. policies may restrict you from consuming any portion of the meal or from receiving any other in-kind benefit in connection with the program and may opt out accordingly. This program and program speakers are sponsored by BridgeBio Inc. Please refer to the program host regarding any questions or concerns.

INDICATION

Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions

Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.

Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

Laboratory Tests

Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m² was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.

Use in Specific Populations

Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy.

There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.